Cardiovascular protection by SGLT2 inhibitors: an integrative review of mechanistic networks, clinical evidence, and safety considerations - Summary - MDSpire

Cardiovascular protection by SGLT2 inhibitors: an integrative review of mechanistic networks, clinical evidence, and safety considerations

  • By

  • Ziyun Wang

  • Yijin Wang

  • Wangning Shangguan

  • Tao Li

  • June 9, 2026

  • 0 min

Share

Objective:

Emphasize the translational framework aspect more explicitly.

Key Findings:
  • Add mention of effects on hard clinical endpoints and the need for dedicated trials for atrial arrhythmias.
Interpretation:

Clarify the connection to ongoing research needs.

Limitations:
  • Include mention of inconsistency of effects on hard clinical endpoints in post-myocardial infarction settings.
Conclusion:

Reiterate the importance of individualized clinical decision-making regarding safety considerations.

Original Source(s)

Cardiovascular protection by SGLT2 inhibitors: an integrative review of mechanistic networks, clinical evidence, and safety considerations

  • by Ziyun Wang, Yijin Wang, Wangning Shangguan, Tao Li

  • June 9, 2026

Related Content

Independent prognostic value of the triglyceride–glucose index and its incremental predictive contribution beyond traditional risk markers in acute heart failure: a retrospective cohort study

Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants

Conduction system pacing compared with biventricular pacing for cardiac resynchronization therapy: a systematic review and meta-analysis